Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Shares Bought by Creative Financial Designs Inc. ADV

Creative Financial Designs Inc. ADV boosted its stake in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 42.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 91,007 shares of the company’s stock after purchasing an additional 27,222 shares during the period. Creative Financial Designs Inc. ADV owned approximately 0.29% of Actinium Pharmaceuticals worth $115,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ATNM. Geode Capital Management LLC grew its holdings in Actinium Pharmaceuticals by 3.0% during the third quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after acquiring an additional 19,843 shares during the period. Vontobel Holding Ltd. acquired a new stake in shares of Actinium Pharmaceuticals during the 4th quarter worth approximately $32,000. Barclays PLC increased its holdings in shares of Actinium Pharmaceuticals by 323.0% during the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after purchasing an additional 32,784 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in shares of Actinium Pharmaceuticals by 25.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock valued at $270,000 after purchasing an additional 42,770 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Actinium Pharmaceuticals in the 3rd quarter valued at $112,000. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Performance

Shares of NYSE ATNM opened at $1.41 on Friday. The firm has a fifty day moving average of $1.20 and a 200 day moving average of $1.46. The firm has a market cap of $43.99 million, a PE ratio of -1.01 and a beta of 0.10. Actinium Pharmaceuticals, Inc. has a one year low of $1.03 and a one year high of $10.24.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.40.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).